Translating preclinical findings to human clinical trials for fatty liver disease is often unreliable due to biological differences.

“what we know about fatty liver disease nled naff any way that you study it the translation from pre-clinical a clinical let alone phase one to phase three does not it's not always born out with a biology given the beauty of the liver and it homeostasis”